POAI · Predictive Oncology Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $6.8K | $72.6K | $8.4K | $18.2K | $45.1K | - | $196.9K | $153.0K | $187.4K | - |
| Gross Profit | - | - | ($4.7K) | ($15.5K) | $65.2K | - | $148.8K | $125.8K | $232.2K | - |
| R&D | - | $2.15M | - | - | - | - | - | - | - | - |
| SG&A | $2.91M | $25.92M | $2.61M | $1.88M | $1.83M | - | $1.58M | $2.14M | $2.63M | - |
| Total Operating Expenses | $2.40M | - | $3.28M | $2.64M | $2.35M | - | $3.32M | $4.29M | $4.47M | - |
| D&A | $28.4K | - | $31.5K | $31.5K | $32.6K | - | $42.7K | $164.2K | $162.6K | - |
| Operating Income | ($7.73M) | ($180.92M) | ($3.28M) | ($2.66M) | ($2.29M) | - | ($2.31M) | ($3.19M) | ($4.24M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.71M) | - | ($77.65M) | ($2.07M) | ($2.44M) | - | ($3.09M) | ($3.18M) | ($4.22M) | - |
| EPS - Basic | ($0.36) | - | ($107.25) | ($0.23) | ($0.34) | - | ($0.48) | ($0.68) | ($1.04) | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.93M | $10.79M | $181.7K | $506.1K | $3.09M | $734.7K | $3.08M | $5.33M | $5.20M | $8.73M |
| Accounts Receivable | $659.3K | $32.1K | $26.0K | $23.0K | $59.8K | $745.6K | $463.8K | $387.0K | $509.4K | $333.7K |
| Inventory | - | - | $38.0K | $42.7K | $45.8K | $385.7K | $504.4K | $568.2K | $441.7K | $494.4K |
| Accounts Payable | $1.35M | $1.84M | $2.72M | $1.35M | $1.21M | $1.14M | $1.14M | $1.56M | $1.73M | $1.34M |
| Current Assets | $37.59M | $42.77M | $1.10M | $1.22M | $3.49M | $2.23M | $4.57M | $6.88M | $6.56M | $10.08M |
| Total Assets | $45.22M | $52.89M | $3.14M | $3.44M | $5.87M | $4.97M | $7.50M | $10.59M | $10.60M | $14.42M |
| Current Liabilities | $4.23M | $4.27M | $79.49M | $3.85M | $4.61M | $3.59M | $3.82M | $4.62M | $4.52M | $3.95M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.95M | $5.17M | $80.57M | $5.09M | $6.01M | $5.18M | $5.53M | $6.49M | $6.55M | $6.15M |
| Stockholders' Equity | $40.27M | $47.72M | ($77.43M) | ($1.65M) | ($145.8K) | ($202.6K) | $1.97M | $4.09M | $4.05M | $8.27M |
| Retained Earnings | ($421.23M) | ($413.52M) | ($262.59M) | ($184.94M) | ($182.87M) | ($180.43M) | ($178.26M) | ($175.16M) | ($171.98M) | ($167.76M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.75M) | - | - | - | ($2.71M) | - | - | - | ($3.42M) | - |
| Investing Cash Flow | ($21.0K) | - | - | - | ($3.0K) | - | - | - | ($3.0K) | - |
| Financing Cash Flow | ($98.2K) | - | - | - | ($112.4K) | - | - | - | ($112.4K) | - |
| CapEx | $21.0K | - | - | - | $0 | - | - | - | $3.0K | - |
| Free Cash Flow | ($3.77M) | - | - | - | ($2.71M) | - | - | - | ($3.42M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.49 | - | - | - | 1.11 | - | - | - | 0.81 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.0% | - | -2475.1% | -60.3% | -41.6% | - | -41.3% | -30.0% | -39.8% | - |
| Return on equity | -19.1% | - | 100.3% | 125.2% | 1675.5% | - | -157.3% | -77.7% | -104.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.89 | 10.02 | 0.01 | 0.32 | 0.76 | 0.62 | 1.20 | 1.49 | 1.45 | 2.55 |
| Quick ratio | 8.89 | 10.02 | 0.01 | 0.31 | 0.75 | 0.51 | 1.06 | 1.37 | 1.35 | 2.43 |
| Cash ratio | 1.64 | 2.53 | 0.00 | 0.13 | 0.67 | 0.20 | 0.81 | 1.15 | 1.15 | 2.21 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.12 | 1.11 | -0.04 | -2.08 | -40.25 | -24.54 | 3.81 | 2.59 | 2.62 | 1.74 |
| Liabilities / Assets | 0.11 | 0.10 | 25.68 | 1.48 | 1.02 | 1.04 | 0.74 | 0.61 | 0.62 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | 0.22 | 0.43 | 0.99 | - | 0.39 | 0.27 | 0.42 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | 1659d | 855d | 370d | - | 935d | 1356d | 860d | - |
| Days payable outstanding | 72565d | 9251d | 118713d | 26973d | 9824d | - | 2117d | 3730d | 3368d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | -71.9% | - | -75.5% | -61.9% | 93.9% | - |
| Operating income growth (YoY) | -237.9% | - | -41.7% | 16.6% | 46.0% | - | 26.6% | 19.4% | -22.3% | - |
| Net income growth (YoY) | -215.6% | - | -2409.2% | 34.9% | 42.1% | - | 2.2% | 18.9% | -23.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -39.0% | - | - | - | 20.7% | - | - | - | 1.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | -83.1% | -72.2% | -78.2% | -62.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$459.4K totalEagan$459.4K · 100.0%
Peer comparison
Same SIC group: Finance Services
Comparing Predictive Oncology Inc. against the 5 most active filers in the same SIC group.